Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Aug 26;63(12):1611–1617. doi: 10.1136/ard.2003.019703

Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis

T Pham 1, A Le Henanff 1, P Ravaud 1, P Dieppe 1, L Paolozzi 1, M Dougados 1
PMCID: PMC1754857  PMID: 15331394

Abstract

Objective: To evaluate long term efficacy of three iterative courses of three weekly intra-articular (IA) injections of NRD101 in the treatment of symptomatic knee osteoarthritis (OA).

Patients and methods: A 1 year prospective, multicentre, randomised, double blind, placebo controlled study of 301 patients aged >50 years with painful and radiological medial knee OA. Patients were randomly assigned into three groups receiving: (1) three courses of three IA injections of hyaluronic acid (HA) + oral placebo; (2) IA injections of saline solution + diacerein 100 mg/day; (3) IA injections of saline solution + oral placebo. Demographic data and symptomatic criteria—pain, Lequesne's index, patient's global assessment of disease activity, percentage of painful days—were obtained during the study; primary structural criterion was JSW. Efficacy criteria were changes in pain VAS, joint space narrowing (JSN), and percentage of progressors (JSN >0.5 mm). An intention to treat analysis was used for symptomatic variables, and completer analysis for structural variables.

Results: Baseline characteristics were similar between the three groups. Mean (SD) improvement in pain VAS was clinically relevant (–33.9 (27.3), n = 301), but with no difference between the groups (p = 0.96). JSW deteriorated (–0.09 (0.55) mm, n = 277, p = 0.01), but with no difference between the groups (p = 0.82). Percentages of progressors were 17.7, 18.9, and 20.3% (p = 0.90), in groups 1, 2, and 3, respectively.

Conclusion: A weak but statistically significant structural deterioration occurred over 1 year, together with clinically relevant symptomatic improvement in patients receiving oral drug and iterative IA injections. Symptomatic and/or structural effects for both this new HA compound and diacerein were not demonstrated.

Full Text

The Full Text of this article is available as a PDF (92.1 KB).

Figure 1.

Figure 1

 Course of the 20 month randomised trial.

Figure 2.

Figure 2

 Change in pain VAS throughout the study according to treatment group.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allard S., O'Regan M. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 2000 Jun;22(6):792–795. doi: 10.1016/s0149-2918(00)90012-2. [DOI] [PubMed] [Google Scholar]
  2. Altman R. D., Hochberg M., Murphy W. A., Jr, Wolfe F., Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995 Sep;3 (Suppl A):3–70. [PubMed] [Google Scholar]
  3. Altman R. D., Moskowitz R. A randomized clinical trial of intra-articular sodium hyaluronate in patients with osteoarthritis of the knee: a summary. Am J Orthop (Belle Mead NJ) 1999 Nov;28(11 Suppl):3–4. [PubMed] [Google Scholar]
  4. Altman R., Brandt K., Hochberg M., Moskowitz R., Bellamy N., Bloch D. A., Buckwalter J., Dougados M., Ehrlich G., Lequesne M. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996 Dec;4(4):217–243. doi: 10.1016/s1063-4584(05)80101-3. [DOI] [PubMed] [Google Scholar]
  5. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol. 2001 Oct;15(4):609–626. doi: 10.1053/berh.2001.0177. [DOI] [PubMed] [Google Scholar]
  6. Brandt K. D., Block J. A., Michalski J. P., Moreland L. W., Caldwell J. R., Lavin P. T. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res. 2001 Apr;(385):130–143. doi: 10.1097/00003086-200104000-00021. [DOI] [PubMed] [Google Scholar]
  7. Brandt K. D., Smith G. N., Jr, Simon L. S. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum. 2000 Jun;43(6):1192–1203. doi: 10.1002/1529-0131(200006)43:6<1192::AID-ANR2>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  8. Creamer P., Hochberg M. C. Osteoarthritis. Lancet. 1997 Aug 16;350(9076):503–508. doi: 10.1016/S0140-6736(97)07226-7. [DOI] [PubMed] [Google Scholar]
  9. Dahlberg L., Lohmander L. S., Ryd L. Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain. A one-year double-blind, placebo-controlled study. Arthritis Rheum. 1994 Apr;37(4):521–528. doi: 10.1002/art.1780370412. [DOI] [PubMed] [Google Scholar]
  10. Dixon A. S., Jacoby R. K., Berry H., Hamilton E. B. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin. 1988;11(4):205–213. doi: 10.1185/03007998809114237. [DOI] [PubMed] [Google Scholar]
  11. Dougados M., Leclaire P., van der Heijde D., Bloch D. A., Bellamy N., Altman R. D. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage. 2000 Nov;8(6):395–403. doi: 10.1053/joca.2000.0361. [DOI] [PubMed] [Google Scholar]
  12. Dougados M., Nguyen M., Berdah L., Maziéres B., Vignon E., Lequesne M., ECHODIAH Investigators Study Group Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001 Nov;44(11):2539–2547. doi: 10.1002/1529-0131(200111)44:11<2539::aid-art434>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  13. Dougados M., Nguyen M., Listrat V., Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage. 1993 Apr;1(2):97–103. doi: 10.1016/s1063-4584(05)80024-x. [DOI] [PubMed] [Google Scholar]
  14. George E. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis. 1998 Nov;57(11):637–640. doi: 10.1136/ard.57.11.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ghosh P., Read R., Numata Y., Smith S., Armstrong S., Wilson D. The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. II. Cartilage composition and proteoglycan metabolism. Semin Arthritis Rheum. 1993 Jun;22(6 Suppl 1):31–42. doi: 10.1016/s0049-0172(10)80017-4. [DOI] [PubMed] [Google Scholar]
  16. Grecomoro G., Martorana U., Di Marco C. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica. 1987;5(2):137–141. [PubMed] [Google Scholar]
  17. Henderson E. B., Smith E. C., Pegley F., Blake D. R. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis. 1994 Aug;53(8):529–534. doi: 10.1136/ard.53.8.529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jones A. C., Pattrick M., Doherty S., Doherty M. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis Cartilage. 1995 Dec;3(4):269–273. doi: 10.1016/s1063-4584(05)80018-4. [DOI] [PubMed] [Google Scholar]
  19. Jordan K. M., Arden N. K., Doherty M., Bannwarth B., Bijlsma J. W. J., Dieppe P., Gunther K., Hauselmann H., Herrero-Beaumont G., Kaklamanis P. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec;62(12):1145–1155. doi: 10.1136/ard.2003.011742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jubb R. W., Piva S., Beinat L., Dacre J., Gishen P. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003 Jul-Aug;57(6):467–474. [PubMed] [Google Scholar]
  21. KELLGREN J. H., LAWRENCE J. S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957 Dec;16(4):494–502. doi: 10.1136/ard.16.4.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Karlsson J., Sjögren L. S., Lohmander L. S. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford) 2002 Nov;41(11):1240–1248. doi: 10.1093/rheumatology/41.11.1240. [DOI] [PubMed] [Google Scholar]
  23. Kirwan J. R., Rankin E. Intra-articular therapy in osteoarthritis. Baillieres Clin Rheumatol. 1997 Nov;11(4):769–794. doi: 10.1016/s0950-3579(97)80009-x. [DOI] [PubMed] [Google Scholar]
  24. Laurent T. C., Fraser J. R. Hyaluronan. FASEB J. 1992 Apr;6(7):2397–2404. [PubMed] [Google Scholar]
  25. Laurent T. C., Laurent U. B., Fraser J. R. Functions of hyaluronan. Ann Rheum Dis. 1995 May;54(5):429–432. doi: 10.1136/ard.54.5.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lawrence R. C., Helmick C. G., Arnett F. C., Deyo R. A., Felson D. T., Giannini E. H., Heyse S. P., Hirsch R., Hochberg M. C., Hunder G. G. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778–799. doi: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  27. Lequesne M., Brandt K., Bellamy N., Moskowitz R., Menkes C. J., Pelletier J. P., Altman R. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol Suppl. 1994 Sep;41:65–73. [PubMed] [Google Scholar]
  28. Listrat V., Ayral X., Patarnello F., Bonvarlet J. P., Simonnet J., Amor B., Dougados M. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage. 1997 May;5(3):153–160. doi: 10.1016/s1063-4584(97)80010-6. [DOI] [PubMed] [Google Scholar]
  29. Lohmander L. S., Dalén N., Englund G., Hämäläinen M., Jensen E. M., Karlsson K., Odensten M., Ryd L., Sernbo I., Suomalainen O. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis. 1996 Jul;55(7):424–431. doi: 10.1136/ard.55.7.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Martel-Pelletier J., Mineau F., Jolicoeur F. C., Cloutier J. M., Pelletier J. P. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998 Apr;25(4):753–762. [PubMed] [Google Scholar]
  31. Moore A. R., Greenslade K. J., Alam C. A., Willoughby D. A. Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage. 1998 Jan;6(1):19–23. doi: 10.1053/joca.1997.0088. [DOI] [PubMed] [Google Scholar]
  32. Moskowitz R. W. Hyaluronic acid supplementation. Curr Rheumatol Rep. 2000 Dec;2(6):466–471. doi: 10.1007/s11926-000-0022-x. [DOI] [PubMed] [Google Scholar]
  33. Nguyen M., Dougados M., Berdah L., Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994 Apr;37(4):529–536. doi: 10.1002/art.1780370413. [DOI] [PubMed] [Google Scholar]
  34. Pelletier J. P., Mineau F., Fernandes J. C., Duval N., Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998 Dec;25(12):2417–2424. [PubMed] [Google Scholar]
  35. Pelletier J. P., Yaron M., Haraoui B., Cohen P., Nahir M. A., Choquette D., Wigler I., Rosner I. A., Beaulieu A. D. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339–2348. doi: 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  36. Peyron J. G. A new approach to the treatment of osteoarthritis: viscosupplementation. Osteoarthritis Cartilage. 1993 Apr;1(2):85–87. doi: 10.1016/s1063-4584(05)80022-6. [DOI] [PubMed] [Google Scholar]
  37. Puhl W., Scharf P. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis. 1997 Jul;56(7):441–441. doi: 10.1136/ard.56.7.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ravaud P., Auleley G. R., Chastang C., Rousselin B., Paolozzi L., Amor B., Dougados M. Knee joint space width measurement: an experimental study of the influence of radiographic procedure and joint positioning. Br J Rheumatol. 1996 Aug;35(8):761–766. doi: 10.1093/rheumatology/35.8.761. [DOI] [PubMed] [Google Scholar]
  39. Ravaud P., Giraudeau B., Auleley G. R., Drape J. L., Rousselin B., Paolozzi L., Chastang C., Dougados M. Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis. 1998 Oct;57(10):624–629. doi: 10.1136/ard.57.10.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Reginster J. Y., Deroisy R., Rovati L. C., Lee R. L., Lejeune E., Bruyere O., Giacovelli G., Henrotin Y., Dacre J. E., Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan 27;357(9252):251–256. doi: 10.1016/S0140-6736(00)03610-2. [DOI] [PubMed] [Google Scholar]
  41. Schiavinato A., Lini E., Guidolin D., Pezzoli G., Botti P., Martelli M., Cortivo R., De Galateo A., Abatangelo G. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. II. Morphological findings. Clin Orthop Relat Res. 1989 Apr;(241):286–299. [PubMed] [Google Scholar]
  42. Towheed T. E., Hochberg M. C. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum. 1997 Apr;26(5):755–770. doi: 10.1016/s0049-0172(97)80043-1. [DOI] [PubMed] [Google Scholar]
  43. Villani P., Bouvenot G. Approche de l'intensité de l'effet placebo dans l'évaluation des anti-arthrosiques symptomatiques d'action lente. Presse Med. 1998 Feb 7;27(5):211–214. [PubMed] [Google Scholar]
  44. Wobig M., Dickhut A., Maier R., Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998 May-Jun;20(3):410–423. doi: 10.1016/s0149-2918(98)80052-0. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES